Neurosyphilis, malaria, and the discovery of antipsychotic agents

Harvard Review of Psychiatry

Volumn 16, Issue 5, 2008, Pages 299-307

  Frankenburg, Frances R ^a,b,c   Baldessarini, Ross J ^c,d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MCLEAN HOSPITAL   (United States)

Author keywords

Aniline dyes; Antipsychotics; Chlorpromazine; Fever therapy; Malaria; Neurosyphilis; Phenothiazines; Quinine

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; BARBITURIC ACID DERIVATIVE; CHLOROQUINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; HERBACEOUS AGENT; MEPACRINE; MERCURY; METHYLENE BLUE; NEUROLEPTIC AGENT; OLANZAPINE; PENICILLIN G; PERPHENAZINE; PHENOTHIAZINE; PHENOTHIAZINE DERIVATIVE; PROMAZINE; PROMETHAZINE; QUETIAPINE; QUININE; RISPERIDONE; SULFAMIDOCHRYSOIDINE; TUBERCULIN; TURPENTINE; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; ANTIBIOTIC THERAPY; ASPIRATION PNEUMONIA; BIPOLAR DISORDER; BRADYKINESIA; CINCHONA CALISAYA; CINCHONISM; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG STRUCTURE; DRUG SYNTHESIS; DYSTONIA; ENTEROPATHY; EPILEPSY; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARING IMPAIRMENT; HISTORY OF MEDICINE; HUMAN; MALARIA; MANIA; MEDICINAL PLANT; MENTAL DISEASE; MONOTHERAPY; NAUSEA AND VOMITING; NEUROSYPHILIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL; PSYCHOSIS; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SKIN DISCOLORATION; STREPTOCOCCUS INFECTION; TARDIVE DYSKINESIA; TINNITUS; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTIMALARIALS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHLORPROMAZINE; EUROPE; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYPERTHERMIA, INDUCED; MALARIA, CEREBRAL; NEUROSYPHILIS; PHENOTHIAZINES; SCHIZOPHRENIA; UNITED STATES;

EID: 52449132307     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1080/10673220802432350     Document Type: Review

References (49)

1. Hutto B. Syphilis in clinical psychiatry: a review. Psychosomatics 2001;42:453-60.
2. Chernin E. The malariatherapy of neurosyphilis. J Parasitol 1984;70:611-7.
3. Wagner-Jauregg J. The treatment of general paresis by inoculation of malaria. J Nerv Ment Dis 1922;55:369-75.
4. Austin SC, Stolley PD, Lasky T. History of malariotherapy for neurosyphilis. JAMA 1992;268:516-9.
5. Braslow JT. Effect of therapeutic innovation on perception of disease and the doctor-patient relationship: history of general paralysis of the insane and malaria fever therapy 1910-1950. Am J Psychiatry 1995;152:660-5.
6. Braslow JT. Mental ills and bodily cures: psychiatric treatment in the first half of the twentieth century. Berkeley: University of California Press, 1997.
7. Garfield S. Mauve: how one man invented a colour that changed the world. London: Faber & Faber, 2000.
8. Honigsbaum M. The fever trail. In search of the cure for malaria. New York: Farrar, Straus & Giroux, 2001.
9. Marquardt M. Paul Ehrlich. New York: Henry Schuman, 1951.
10. Mann J. The elusive magic bullet. Oxford: Oxford University Press, 1999.
11. Swazey J. Chlorpromazine in psychiatry: a study of therapeutic innovation. Cambridge, MA: MIT Press, 1974.
12. Baldessarini RJ. Chemotherapy in psychiatry: principles and practice. Cambridge, MA: Harvard University Press, 1985.
13. Seeman JI. The Woodward-Doering/Rabe-Kindler total synthesis of quinine: setting the record straight. Angew Chem Int Ed Engl 2007;46:1378-1413.
14. Stork G, Niu D, Fujimoto A, et al. The first stereoselective total synthesis of quinine. J Am Chem Soc 2001;123:3239-42.
15. Weinreb SM. Synthetic lessons from quinine. Nature 2001;411:429-31.
16. Smocovitis VB. Desperately seeking quinine. Mod Drug Discov 2003;May:57-8.
17. Kanigel R. Apprentice to genius: the making of a scientific dynasty. Baltimore: Johns Hopkins University Press, 1983.
18. Laborit H, Huguenard P, Alluaume R. Un nouveau stabilisateur végétatif (le 4560 RP). Presse Med 1952;60:206-8.
19. Hamon J, Paraire J, Velluz J. Rémarques sur l'action du 4560 RP sur l'agitation maniaque. Ann Med Psychol 1952;110:331-5.
20. Delay J, Deniker P, Harl JM. Utilization en thérapeutique psychiatrique d'une phénothiazine d'action centrale élective. Ann Med Psychol 1952;110:112-7.
21. Delay J, Deniker P. Chlorpromazine and neuroleptic treatments in psychiatry. J Clin Exp Psychopathol 1956;17:19-24.
22. Deniker P. From chlorpromazine to tardive dyskinesia: brief history of the neuroleptics. Psychiatr J Univ Ott 1989;14:253-9.
23. Thuillier J. Ten years that changed the face of mental illness. London: Martin Dunitz, 1999.
24. Healy D. The creation of psychopharmacology. Cambridge, MA: Harvard University Press, 2002.
25. Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2005;461-500.
26. Narsapur SL, Naylor GJ. Methylene blue: a possible treatment for manic-depressive psychosis. J Affect Disord 1983;5:155-61.
27. Naylor GJ, Martin B, Hopwood SE, Watson Y. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry 1986;21:915-20.
28. Deutsch SI, Rosse RB, Schwartz BL, Fay-McCarthy M, Rosenberg PB, Fearing K. Methylene blue adjuvant therapy of schizophrenia. Clin Neuropharmacol 1997;20:357-63.
29. Berger JR. Neurosyphilis. Curr Treat Options Infect Dis 2002;4:69-74.
30. Schofer H, Imhof M, Thoma-Greber E, et al. Active syphilis in HIV infection: a multicentre retrospective survey. Genitourin Med 1996;72:176-81.
31. Speilman A, D'Antonio M. Mosquito. The story of man's deadliest foe. London: Faber & Faber, 2001.
32. Desowitz RS. Federal bodysnatchers and the New Guinea virus: tales of parasites, people, and politics. New York: W.W. Norton, 2002.
33. Farooq U, Mahajan RC. Drug resistance in malaria. J Vector Borne Dis 2004;41:45-53.
34. Kalkanidis M, Klonis N, Tilley L, Deady LW. Novel phenothiazine antimalarials: synthesis, antimalarial activity, and inhibition of the formation of beta-haematin. Biochem Pharmacol 2002;63:833-42.
35. Meissner PE, Mandi G, Witte S, et al. Safety of methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso. Malar J 2005;4:45.
36. Meissner PE, Mandi G, Coulibaly B, et al. Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malar J 2006;5:84.
37. Takasu K, Shimogama T, Sataoh C, Kaiser M, Brun R, Ihara M. Synthesis and antimalarial property of orally active phenoxazinium salts. J Med Chem 2007;50:2281-4.
38. Kremsner PG, Krishna S. Antimalarial combinations. Lancet 2004;364:285-94.
39. Idro R, Ndiritu M, Ogutu B, et al. Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children. JAMA 2007;297:2232-40.
40. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: critical overview. CMAJ 2005;172:1703-11.
41. Baldessarini RJ, Frankenburg FR. Clozapine. N Engl J Med 1991;324:746-54.
42. Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006;63:1079-87.
43. Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007;164:428-36.
44. Chakos MH, Glick ID, Miller AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006;57:1094-1101.
45. Centorrino F, Cincotta SL, Talamo A, et al. Hospital use of antipsychotic drugs: polytherapy. Compr Psychiatry 2008;49:65-9.
46. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 2006;20:29-42.
47. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Prescribing patterns of psychotropic medicines in the United States for patients diagnosed with bipolar disorders. Psychiatr Serv 2007;58:85-91.
48. Ghaemi SN, ed. Polypharmacy in psychiatry. New York: Marcel Dekker, 2002.
49. Yildiz A, Guleryuz S, Ankerst DP, Ongür D, Renshaw PF. Protein kinase C inhibition in the treatment of mania: a doubleblind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 2008;65:255-63.